🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07028606
Active, not recruiting Phase 1

Vertical Ridge Augmentation Using Computer-guided Sandwich Osteotomy Technique

NCT07028606 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 1
Started
2024-05-09
Last updated
2025-06-19

Condition(s) studied

Alveolar Bone Resorption

Investigational drug(s) / intervention(s)

Sandwich technique with xenograft, collagen membrane and simultaneous implant placement.Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.

Sandwich technique with xenograft, collagen membrane and simultaneous implant placement.: All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft. Osteotomy for implant will be carried out with advanced kit of roott\_system Switzerland brand, sandwich osteotomy technique will be carried out with three full thickness cuts using the tungsten carbide disc were performed in the form of two vertical cuts away from the neighboring teeth by 3 mm and one horizontal bony cut on the labial surface of alveolar ridge. Bone splitting chisels were used in sequential width (2 mm, 3 mm) and lightweight mallet to complete splitting of the bony segment, the surgical sites will be irrigated with sterile saline. Surgical flaps will be sutured to the pre-surgical level.

Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.: All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft with and with RGD. Injectable RGD-bioconjugate Mussel Adhesive Proteins (RGD-MAPs) composite hydroxypropyl methylcellulose (HPMC) hydrogels . Previously we developed a novel type of injectable self-supported hydrogel (2 mg/ml of RGD-MAPs/HPMC) based porcine nano hydroxyapatite (MPH) for dental graft, which could good handling property, biodegradation or biocompatibility with the hydrogel disassembly and provided efficient cell adhesion activity and no inflammatory responses. Surgical flaps will be sutured to the pre-surgical level with 4-0 polyproline non resorbable suture utilizing a single interrupted suturing technique.

Study summary

Researcher will introduce the trial to patients and provide full explanation of its aim and benefits in Arabic language. Patients will then be able to have an informed discussion with the researcher. Researcher will obtain written consent from patients willing to participate in the trial

Eligibility

Sex
ALL
Min age
30 Years
Max age
45 Years
Healthy volunteers
No
Inclusion criteria * Adults (age 30-45) with vertical ridge deficiency. * Patients with maxillary vertical ridge deficiency 4-8mm according to Cologne Classification of Alveolar Ridge Defects (CCARD). * Patients with good oral hygiene. * Free from systemic diseases that may influence the outcome of the therapy. Exclusion criteria * Systemic conditions which are generally considered to be a contraindication to implant surgery which included but not limited to: osteoporosis, uncontrolled diabetes. * Pregnant or lactating females * Current or former smokers. * Patient treated by immunosuppressive chemotherapy or radio therapy, * Allergy to any material or medication used in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Al-Azhar University, Cairo, Boys Cairo Nasr City

More Al-Azhar University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07028606 on ClinicalTrials.gov ↗ ← All trials in Egypt